Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.85
Dollar change
+0.01
Percentage change
0.54
%
Index- P/E- EPS (ttm)-14.28 Insider Own1.83% Shs Outstand2.17M Perf Week-2.63%
Market Cap4.01M Forward P/E- EPS next Y-1.98 Insider Trans80.19% Shs Float2.13M Perf Month-31.73%
Income-25.97M PEG- EPS next Q-2.96 Inst Own9.62% Short Float0.78% Perf Quarter-66.21%
Sales0.00M P/S- EPS this Y59.48% Inst Trans- Short Ratio0.41 Perf Half Y-75.86%
Book/sh2.91 P/B0.63 EPS next Y65.80% ROA-127.82% Short Interest0.02M Perf Year-80.94%
Cash/sh2.97 P/C0.62 EPS next 5Y- ROE-160.47% 52W Range1.82 - 11.82 Perf YTD-65.84%
Dividend Est.- P/FCF- EPS past 5Y92.12% ROI-450.55% 52W High-84.35% Beta2.92
Dividend TTM- Quick Ratio2.24 Sales past 5Y-20.34% Gross Margin30.96% 52W Low1.65% ATR (14)0.20
Dividend Ex-Date- Current Ratio2.24 EPS Y/Y TTM-6.82% Oper. Margin0.00% RSI (14)31.63 Volatility6.87% 8.42%
Employees17 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price82.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-26.06% Payout- Rel Volume0.34 Prev Close1.84
Sales Surprise- EPS Surprise-41.90% Sales Q/Q- EarningsFeb 29 AMC Avg Volume40.06K Price1.85
SMA20-12.26% SMA50-33.47% SMA200-71.28% Trades Volume13,516 Change0.54%
Date Action Analyst Rating Change Price Target Change
Nov-19-20Initiated Maxim Group Buy $8
Mar-12-24 09:00AM
Mar-06-24 09:00AM
Mar-02-24 08:45AM
Feb-29-24 04:00PM
Feb-22-24 09:00AM
09:00AM Loading…
Feb-19-24 09:00AM
Feb-13-24 09:00AM
Feb-06-24 09:00AM
Jan-29-24 09:00AM
Jan-08-24 09:00AM
Jan-04-24 09:00AM
Jan-03-24 09:00AM
Dec-27-23 09:00AM
Dec-19-23 09:00AM
Dec-06-23 07:00AM
07:00AM Loading…
Dec-05-23 07:00AM
Nov-30-23 04:30PM
Nov-29-23 09:00AM
Nov-28-23 09:00AM
Nov-14-23 09:00AM
Nov-10-23 10:24AM
Nov-08-23 04:00PM
Nov-01-23 07:00AM
Oct-31-23 09:00AM
07:00AM
Oct-30-23 09:00AM
Oct-25-23 09:00AM
Oct-24-23 09:00AM
Oct-09-23 09:00AM
Oct-05-23 09:00AM
07:00AM Loading…
Oct-04-23 07:00AM
Oct-03-23 07:00AM
Sep-27-23 09:00AM
Sep-26-23 09:00AM
Sep-21-23 09:35AM
Sep-20-23 09:00AM
Sep-19-23 09:00AM
Sep-12-23 09:00AM
Sep-11-23 09:00AM
Aug-31-23 09:00AM
Aug-29-23 09:00AM
Aug-28-23 09:00AM
Aug-11-23 12:47PM
Aug-10-23 09:00AM
Aug-09-23 04:00PM
Jul-26-23 09:00AM
Jul-24-23 09:00AM
Jul-20-23 09:00AM
Jul-10-23 09:00AM
Jun-28-23 09:00AM
Jun-27-23 10:15AM
May-31-23 09:00AM
May-25-23 09:00AM
May-24-23 04:32PM
08:00AM
May-15-23 09:00AM
May-09-23 09:00AM
May-04-23 04:00PM
Apr-26-23 09:00AM
Apr-25-23 09:00AM
Apr-17-23 09:00AM
Apr-06-23 10:00AM
Apr-05-23 01:30PM
Mar-30-23 11:00AM
Mar-27-23 07:08AM
Mar-23-23 04:00PM
Mar-15-23 09:00AM
Mar-09-23 09:00AM
Mar-06-23 09:00AM
Feb-27-23 09:00AM
Feb-15-23 09:00AM
Feb-08-23 09:00AM
Feb-07-23 09:00AM
Jan-26-23 09:00AM
Jan-25-23 11:00AM
Jan-04-23 09:00AM
Dec-20-22 09:00AM
Dec-07-22 04:00PM
Nov-28-22 10:15AM
Nov-11-22 05:46AM
Nov-09-22 04:00PM
Oct-31-22 10:33AM
Oct-26-22 09:00AM
Oct-11-22 09:00AM
Oct-06-22 09:00AM
Sep-07-22 09:00AM
Sep-01-22 09:00AM
Aug-18-22 10:27AM
Aug-17-22 09:29AM
Aug-10-22 09:13AM
Aug-09-22 06:30AM
Aug-03-22 04:00PM
Jul-28-22 09:00AM
Jul-26-22 09:00AM
Jul-08-22 02:34PM
Jun-13-22 09:00AM
Jun-07-22 09:00AM
May-25-22 01:47PM
May-24-22 09:00AM
08:39AM
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DODD DAVID APresident, CEOFeb 22 '24Buy2.278,20918,66318,661Feb 22 04:41 PM
DODD DAVID APresident, CEOFeb 21 '24Buy2.155201,11810,452Feb 22 04:41 PM
Reynolds MarkCFOFeb 07 '24Buy2.772,0005,5407,213Feb 07 04:43 PM
McKee Kelly T. Jr.Chief Medical OfficerDec 22 '23Buy0.366,9442,50035,782Dec 26 03:51 PM
McKee Kelly T. Jr.Chief Medical OfficerSep 25 '23Buy0.529,6535,02028,838Sep 27 04:33 PM
DODD DAVID APresident, CEOAug 25 '23Buy0.5735,08720,000148,957Aug 28 04:05 PM
Reynolds MarkCFOAug 18 '23Buy0.5210,0005,17978,184Aug 21 08:39 AM
DODD DAVID APresident, CEOApr 24 '23Buy0.6432,00020,445113,870Apr 25 03:13 PM
Reynolds MarkCFOApr 20 '23Buy0.638,0005,04068,184Apr 21 08:38 AM